Denali Therapeutics Inc. (DNLI)

Denali Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 18, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	4,488	2,966	3,777	5,447	10,044	1,673
Market Cap Growth	-18.03%	-21.48%	-30.66%	-45.77%	500.43%	-14.73%
Enterprise Value	3,094	1,902	2,733	4,153	9,133	1,243
Last Close Price	30.68	21.46	27.81	44.60	83.76	17.42
PE Ratio	-	-20.30	-10.71	-18.65	132.95	-8.42
PS Ratio	2613.56	8.97	34.82	111.93	29.92	62.71
PB Ratio	3.17	2.88	3.62	5.66	8.73	4.24
P/FCF Ratio	-8.24	-8.00	-14.39	-24.77	24.32	-9.87
P/OCF Ratio	-8.47	-8.28	-15.43	-25.77	24.14	-11.04
EV/Sales Ratio	2442.01	5.76	25.20	85.35	27.21	46.60
EV/EBITDA Ratio	-3.91	-10.13	-8.27	-14.46	128.18	-6.06
EV/EBIT Ratio	-3.91	-9.67	-8.02	-14.04	145.62	-5.83
EV/FCF Ratio	-4.81	-5.13	-10.41	-18.89	22.11	-7.33
Debt / Equity Ratio	0.04	0.05	0.06	0.07	0.06	0.18
Debt / EBITDA Ratio	-	-	-	-	0.87	-
Debt / FCF Ratio	-0.12	-0.14	-0.23	-0.29	0.17	-0.43
Asset Turnover	0.00	0.25	0.08	0.03	0.31	0.04
Quick Ratio	12.04	13.31	3.70	2.29	20.58	9.16
Current Ratio	12.46	13.65	3.77	2.37	20.86	9.48
Return on Equity (ROE)	-32.61%	-14.01%	-32.52%	-27.51%	9.21%	-41.97%
Return on Assets (ROA)	-22.04%	-9.41%	-14.87%	-12.29%	3.63%	-21.93%
Return on Capital (ROIC)	-23.11%	-11.25%	-20.01%	-16.46%	4.65%	-26.27%
Earnings Yield	-9.55%	-4.90%	-8.63%	-5.33%	0.71%	-11.81%
FCF Yield	-9.15%	-12.51%	-6.95%	-4.04%	4.11%	-10.13%
Buyback Yield / Dilution	-12.10%	-9.43%	-3.30%	-7.83%	-17.88%	-3.22%
Total Shareholder Return	-12.10%	-9.43%	-3.30%	-7.83%	-17.88%	-3.22%

Source: S&P Capital IQ. Standard template. Financial Sources.